文献速递围术期管理与 ERAS急腹症与外科感染

局部外用氨甲环酸预防手术出血的系统评价与荟萃分析

Prophylactic Topical Tranexamic Acid Versus Placebo in Surgical Patients: A Systematic Review and Meta-analysis∗.
PubMed 文献 · Ann Surg · 2021-01-01

该研究系统检索并定量分析了71项平行组随机对照试验(共7539例成人手术患者),比较局部外用氨甲环酸与安慰剂的效果。结果显示局部TXA显著减少术中失血量、总失血量及输血发生率,并缩短住院时间,且未观察到死亡率、肺栓塞、深静脉血栓等不良事件增加。

要点

  • 局部外用TXA可显著降低成人手术患者输血发生率(OR 0.30)。
  • 局部TXA减少术中失血量(MD -36.83 mL)和总失血量(MD -319.55 mL)。
  • 未观察到局部TXA增加死亡率、肺栓塞、深静脉血栓等不良事件。

核心结论

  • 在71项试验7539例成人手术患者的荟萃分析中,局部外用TXA减少输血发生率且未观察到相关不良事件。

研究设计与样本

  • 系统评价与荟萃分析,检索EMBASE、MEDLINE、CENTRAL和ISI Web of Science自建库至2019年5月31日。
  • 纳入平行组随机对照试验,共71项试验7539例参与者(骨科5450例,非骨科1909例)。

主要发现

  • 与安慰剂相比,局部TXA显著减少术中失血量(MD -36.83 mL,95%CI -54.77至-18.88,P<0.001)。
  • 局部TXA显著减少总失血量(MD -319.55 mL,95%CI -387.42至-251.69,P<0.001)。
  • 局部TXA显著降低输血发生率(OR 0.30,95%CI 0.26-0.34,P<0.001)。
  • 局部TXA组住院时间更短(MD -0.28天,95%CI -0.47至-0.08,P=0.006)。
  • 死亡率(OR 0.78,95%CI 0.45-1.36,P=0.39)、肺栓塞(OR 0.73,95%CI 0.27-1.93,P=0.52)、深静脉血栓(OR 1.07,95%CI 0.65-1.77,P=0.79)、心肌梗死(OR 0.79,95%CI 0.21-2.99,P=0.73)、卒中(OR 0.85,95%CI 0.28-2.57,P=0.77)均无显著差异。

临床怎么用

  • 成人手术患者可考虑局部外用TXA以减少失血和输血需求,且未观察到血栓栓塞事件增加。

局限性

  • 纳入研究中20项偏倚风险为低、26项不清楚、25项为高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Perioperative bleeding remains a major concern to all clinicians caring for perioperative patients. Due to the theoretical risk of thromboembolic events associated with tranexamic acid (TXA) when administered intravenously, topical route of TXA has been extensively studied, but its safety and efficacy profile remain unclear in the literature. The primary aim of this review was to assess the effect of topical TXA on incidence of blood transfusion and mortality in adults undergoing surgery. DATA SOURCES: EMBASE, MEDLINE, CENTRAL, and ISI Web of Science were systematically searched from their inception until May 31, 2019. REVIEW METHODS: Parallel-arm randomized controlled trials were included. RESULTS: Seventy-one trials (7539 participants: orthopedics 5450 vs nonorthopedics 1909) were included for quantitative meta-analysis. In comparison to placebo, topical TXA significantly reduced intraoperative blood loss [mean difference (MD) -36.83 mL, 95% confidence interval (CI) -54.77 to -18.88, P < 0.001], total blood loss (MD -319.55 mL, 95% CI -387.42 to -251.69, P < 0.001), and incidence of blood transfusion [odds ratio (OR) 0.30, 95% CI 0.26-0.34, P < 0.001]. Patients who received topical TXA were associated with a shorter length of hospital stay (MD -0.28 days, 95% CI -0.47 to -0.08, P = 0.006). No adverse events associated with the use of topical TXA were observed, namely mortality (OR 0.78, 95% CI 0.45-1.36, P = 0.39), pulmonary embolism (OR 0.73, 95% CI 0.27-1.93, P = 0.52), deep vein thrombosis (OR 1.07, 95% CI 0.65-1.77, P = 0.79), myocardial infarction (OR 0.79, 95% CI 0.21-2.99, P = 0.73), and stroke (OR 0.85, 95% CI 0.28-2.57, P = 0.77). Of all included studies, the risk of bias assessment was "low" for 20 studies, "unclear" for 26 studies and "high" for 25 studies. CONCLUSIONS: In the meta-analysis of 71 trials (7539 patients), topical TXA reduced the incidence of blood transfusion without any notable adverse events associated with TXA in adults undergoing surgery. PROSPERO: CRD 42018111762.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Teoh WY, Tan TG, Ng KT, et al. Prophylactic Topical Tranexamic Acid Versus Placebo in Surgical Patients: A Systematic Review and Meta-analysis∗. Ann Surg. 2021. PMID: 32282377. doi:10.1097/SLA.0000000000003896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。